GlobeNewswire by notified

Ensurge Micropower ASA; Announcement on Organizational Changes and Commercial Update

Share

Oslo, Norway 6 January 2023.

Ensurge Micropower ASA (“Ensurge” or the “Company”) today announces the implementation of certain organizational changes and provides a commercial update, including plans going forward.

Change of CEO:

Ensurge hereby announces that Mark Newman will assume the role as Interim Chief Executive Officer of Ensurge and its US subsidiary, commencing on or about 8 February 2023. Mark will be based in San Jose, California. He will replace Kevin Barber, who has been the CEO since November 2018. Mark is presently a member of the Board of Directors of the Company. Due to applicable legal requirements, he will temporarily resign from the Board while serving as Interim CEO. Board election will be an agenda item at an upcoming extraordinary general meeting to be called and the nomination committee will be asked to identify and propose suitable candidate(s) for the Board prior to such general meeting.

Mark, who is a British citizen, has served on the Board of Ensurge since 25 May 2022. He is founder and CEO of Electric Revolution Ventures, and is a renowned expert, advisor and investor in batteries, semiconductors, and electric vehicles. Mark was the top ranked analyst and lead author of Bernstein’s all time most read research globally, “Electric Revolution” and “Battery Bible”, and is a frequent speaker and commentator on these topics. He spent over a decade as Managing Director and Senior Analyst covering technology at Bernstein, where he spearheaded the Electric Revolution thematic research covering batteries, semiconductors, and the entire electric vehicle value chain. 

Previously, Mark was Director of Strategy at Samsung in Korea, where he led several strategic initiatives, venture investments and acquisitions. He also worked at Applied Materials in California, supporting the world’s leading semiconductor manufacturing companies in the United States, Europe, and Asia. Mark was a seed investor and until recently Chief Commercial Officer and Head of Strategy at fast-charge battery pioneers, Nyobolt. He has been an active investor in several other start-ups and advisor to Ivanhoe Capital Acquisition and SES.ai, that recently combined (now SES.ai) and listed on the New York Stock Exchange. Mark currently serves on the board of the Faraday Institution (the UK’s flagship battery research program). 

Mark holds a Master’s in Chemical Engineering from University College London, and an MBA from Harvard Business School. 

The Company is delighted that Mark Newman, with his deep knowledge of the battery industry and business, proven track-record in executive management, and good knowledge of Ensurge based on his position on the Board, wishes to take the position as Interim CEO. 

As Mark is a non - EEA or UK resident, his appointment as interim CEO of Ensurge Micropower ASA requires an exemption from the residence requirements under the Public Limited Companies Act. Ensurge will immediately file for such an exemption with the Ministry of Trade, Industries and Fisheries.

The Company also takes this opportunity to express its appreciation to Kevin Barber for his many years of service to the Company as Chief Executive Offier. Kevin was instrumental in the Company’s change of business strategy in 2020 to design and develop rechargeable solid- state lithium microbatteries and the subsequent development and growth of the Company.

Commercial Update and Plans

Ensurge has made significant progress since announcing its updated business strategy in January 2020. The Company received the first production order for 150,000 units of its rechargeable 1-100 milliampere (mAh) solid-state lithium micro-batteries in December 2022. The Company remains in deep discussions with strategic partners and customers with a multinational reach, and there is a strong pipeline of exciting customer leads, within a wide range of industries and business segments.

Consequently, the Company is now in a position to capture a significant share of the large global market for micro-batteries. Ensurge makes both core battery cell technology and fully packaged batteries and will continue to market and sell both offerings. The market continues to grow and the interest from potential customers looking for Ensurge’s cells and batteries is thus increasing.

In the short term, and to better position the Company for further commercialization and growth, measures will be taken to reduce costs and cash burn. All expenditures will be reviewed with the objective to cut costs meaningfully. The financial restructuring of the Company will include raising funds through the US subsidiary, a possible listing of the US subsidiary, and other measures that will strengthen the long-term positioning of Ensurge.

Work with key customers and strategic partners will be intensified, with the aim for Ensurge to reach commercial agreements, which, in turn, will enable the Company to invest in roll-to-roll equipment to be able to serve the existing strong demand in the market.  

There will be a focus on maintaining a stable team and operations. The key technical team in San Jose, California remains fully dedicated with a firm belief in the Company’s technology and commercial potential.

As the appointment of Mark Newman as CEO is intended as interim in nature, the Company will seek to find a permanent CEO.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5 -12 of the Norwegian Securities Trading Act. This stock exchange release was published by Ståle Bjørnstad, VP, Corporate Development and IR, on 6 February 2023 at 0800 CET.

For more information about Ensurge's microbattery technology visit the Company's website, www.ensurge.com. 

Contact: Ståle Bjørnstad - Investor Relations Email: stale.bjornstad@ensurge.com (mailto:stale.bjornstad@ensurge.com) Phone: +47 99 16 76 72 

About Ensurge Micropower Ensurge is Energizing Innovation (TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1-100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye